Disc Medicine
Open
$68.16
Prev. Close
$68.00
High
$68.16
Low
$67.93
Market Snapshot
$2.59B
-10.7
-3.99
155
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
NEXTBio Capital acquired 42,778 shares of Disc Medicine, reflecting growing investment interest, while the company faces legal scrutiny following FDA-related stock fluctuations.
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Recently from Cashu
Disc Medicine Stock Boosted by PharmaNutra's WHO Recognition for Sucrosomial® Iron Innovation
PharmaNutra's Sucrosomial® Iron Gains WHO Recognition, Paving the Way for Better Patient Management PharmaNutra S.p.A., an Italian pharmaceutical company, achieves a milestone with its patented oral f…
Disc Medicine's Strategic Financing Fuels Branding Iron Holdings' Growth in Protein Sector
Strategic Financing Boosts Branding Iron Holdings' Growth Potential In a significant development within the food sector, Platinum Equity announces its financing support for Branding Iron Holdings, a c…
Disc Medicine: Strategic Financing Fuels Branding Iron Holdings' Growth in Protein Sector
Strategic Financing Propels Branding Iron Holdings' Growth Ambitions Platinum Equity's recent financing provision to Branding Iron Holdings marks a significant step in the food production sector, part…